Beta

A cancer drug is being touted online as a way to grow taller – what you need to know

Featured image for article: A cancer drug is being touted online as a way to grow taller – what you need to know
This is a review of an original article published in: theconversation.com.
To read the original article in full go to : A cancer drug is being touted online as a way to grow taller – what you need to know.

Below is a short summary and detailed review of this article written by FutureFactual:

Erdafitinib heightmaxxing: Cancer drug linked to rapid growth in children raises safety concerns

Overview

The Conversation discusses erdafitinib, a targeted cancer drug, and its unexpected association with rapid growth spurts in some children and teenagers undergoing treatment for brain tumours.While this height increase has sparked interest in heightmaxxing, experts caution that the same drug may disrupt normal bone development and carry other serious risks.

  • Erdafitinib is an FGFR inhibitor approved for advanced bladder cancer and used experimentally for certain brain tumours in children.
  • Reports describe unusually fast growth in two Vienna brain-tumour cases and a dramatic nine‑month growth spurt of a 15‑year‑old, but such observations involve very small, ill patients and may not apply to healthy adolescents.
  • Height gains could be accompanied by skeletal deformities, and the drug can raise phosphate levels and cause eye problems, among other side effects.
  • Social media trends around heightmaxxing may push some teens to experiment with unproven treatments, underscoring the need for rigorous clinical evidence and caution.

Author: The Conversation

Overview

The article reviews emerging observations that erdafitinib, a targeted therapy that blocks fibroblast growth factor receptors (FGFRs), can stimulate rapid growth in some children treated for brain tumours. While this has generated interest in the possibility of increasing final height, the piece emphasises significant caveats about safety, mechanism, and the limits of current evidence.

What erdafitinib does and why it matters for bone growth

Erdafitinib is a targeted cancer drug approved for FGFR3-altered advanced bladder cancer and used experimentally in select pediatric brain tumours. FGFR signals regulate cell growth and survival, and erdafitinib’s action on these receptors can slow cancer progression but also affect healthy tissues, including developing bones. Growth plates, cartilage, and bone formation are influenced by FGFR signalling, particularly FGFR3, which normally restrains bone growth. By inhibiting FGFRs, erdafitinib may theoretically reduce this brake, potentially increasing height in growing individuals. However, this potential benefit is entangled with risks to skeletal development and overall health.

Case reports fueling heightmaxxing discussions

The excitement largely stems from a Vienna report describing two children with brain tumours who showed unexpectedly rapid growth while on erdafitinib. In another, a 15-year-old treated for a brain tumour grew about 14.3 cm over nine months, a rate far beyond normal puberty-related growth. Importantly, these cases involved serious illness and concurrent treatments, so they cannot establish that erdafitinib would produce lasting height gains in healthy adolescents or that such gains would be proportionate and safe.

Risks and biological limits

Blocking FGFRs in growing individuals can disrupt multiple tissues beyond bone, including eyes and mineral metabolism. Observed side effects include elevated phosphate levels in the blood, risk of abnormal mineral deposits, and potentially serious eye complications. Even if height increases occur, they may come at the cost of skeletal weakness, spinal deformities, or impaired bone mineralisation. After puberty, growth plates fuse and further lengthening is unlikely, making any height increase at that stage improbable and risky.

Heightmaxxing and the need for rigorous science

Heightmaxxing reflects broader cultural pressures around appearance, especially among young men, and social media can amplify the obsession with marginal gains. TikTok has moved to ban some accounts promoting heightmaxxing, but the social dynamics persist. The article stresses that turning an unexpected side-effect into a therapeutic strategy would require robust clinical trials, careful dosing, and long-term monitoring to ensure safety and healthy skeletal outcomes.

Bottom line

Erdafitinib’s height-related effects observed in a small number of patients do not constitute evidence that healthy adolescents can safely become taller using the drug. The balance of potential height benefits against eye problems, phosphate elevations, and skeletal deformities argues for caution and further research rather than self-experimentation. The findings may inform future studies into FGFR signalling and skeletal growth disorders, but they do not justify premature use by healthy teenagers.